News

DA Davidson Increases Clorox Price Target Amid Strong Growth

DA Davidson Increases Clorox Price Target Amid Strong Growth

Overview of Clorox's Performance

Recently, Clorox (NYSE: CLX) captured attention in the market as DA Davidson raised its price target for the company from $153.00 to $171.00. This adjustment comes after Clorox reported its first-quarter earnings for fiscal year 2025, which exceeded analysts' expectations. The firm maintained a Neutral rating on the stock despite the positive outlook.

Strong Financial Results

Investors were pleased to hear that Clorox achieved an impressive earnings per share (EPS) of $0.47, surpassing consensus estimates. The company showcased a remarkable 31% growth in organic sales compared to the same quarter last year. This renewal in growth aligns with the company's recovery following a previous cyberattack that had significantly impacted their sales.

Impact of Early Retail Orders

Moreover, Clorox's strong sales can be partly attributed to retailers ordering products geared towards the flu season well ahead of schedule. This strategic move propelled a surge in sales during the first quarter of fiscal 2025, as purchases were drawn forward from what typically would have been the second quarter.

Market Recovery and Guidance Adjustments

Clorox has successfully reclaimed its market share, returning to levels observed prior to the cyber incident. In light of this impressive performance, the company has slightly adjusted its full-year EPS guidance upward by $0.10. Responding to these trends, DA Davidson has increased their projection for Clorox’s organic sales growth in fiscal year 2025 from 4% to a more optimistic 5%.

Future Predictions

Furthermore, DA Davidson has proactively updated its financial models, now forecasting for fiscal year 2027. The newly established price target of $171 is based on a multiple of 25 times the anticipated EPS of $6.83 for calendar year 2026. This revision not only reflects the analyst's updated expectations but also reiterates confidence in Clorox’s improved market position.

Analyst Perspectives

In parallel news, Jefferies has maintained a Buy rating for Clorox's stock while slightly adjusting their price target, moving it from $187 to $188. The market analyst has acknowledged Clorox’s quick response to restoring its market share after the cyberattack in August 2023, which showcases the company’s resilience and agility in overcoming past challenges.

Sales Forecast and Promotional Strategies

Despite the strong growth, Clorox anticipates a decline in sales in the low teens for the second quarter, primarily due to volume pull-forwards. Looking to the latter half of the fiscal year, the company expects organic growth to range between 3% to 5%, showcasing a balanced approach to growth amidst a changing market landscape.

Promotional Spending Plans

The promotional environment for Clorox has returned to pre-COVID levels, and the company has planned strategic promotional spending to further bolster growth. Jefferies recognizes Clorox's proactive stance, particularly the decision to revise their guidance positively following an impressive first quarter.

InvestingPro Insights

The recent developments in Clorox's performance are underpinned by key insights from InvestingPro. The company's market capitalization stands at a substantial $20.19 billion, solidifying its prominent role within the consumer goods sector. Clorox recorded a revenue increase of 6.17% over the last year, reaching $7.47 billion.

Commitment to Shareholder Value

InvestingPro also highlights Clorox's dedication to shareholder value through its remarkable 48 consecutive years of dividend increases. This longstanding commitment reflects a stable business model and a record of consistent profitability. With a moderate level of debt, Clorox enjoys financial flexibility which supports its growth initiatives.

Conclusion

Clorox's stock performance over the past three months has been impressive, with a total return of 15.05%. This positive trend aligns with DA Davidson's optimistic outlook. As Clorox continues to enhance its business strategies and maintain transparency with stakeholders, further insights and updates about the company’s performance are highly anticipated.

Frequently Asked Questions

What is the new price target for Clorox stock?

DA Davidson has raised the price target for Clorox stock to $171.00 from $153.00.

What factors contributed to Clorox's earnings beat?

The earnings beat was primarily driven by a 31% increase in organic sales and early retailer orders related to flu season products.

How has Clorox's market share changed post-cyberattack?

Clorox has successfully recovered its market share levels, reaching pre-cyberattack figures.

What is Clorox's guidance for organic sales growth?

The company estimates organic sales growth to be between 3% to 5% for the latter half of the fiscal year.

How does Clorox’s dividend history reflect its financial health?

Clorox has raised its dividend for 48 consecutive years, showcasing its consistent profitability and commitment to shareholder value.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Business Formations in 2026: A Blow-by-Blow Analysis

Updated Category News Views 91

Surging Entrepreneurial Spirit in 2026 Just when you’d think economic jitters would slow us down, American entrepreneurship is out there smashing records like a bulldozer through a picket fence. September 2026 saw a staggering 562,579 new business formations—the highest September tally ever logged. That's no fluke. This momentum hasn’t let up all year, and it paints...

Continue Reading
Clarivoy's AI-Driven Leap into Automotive Data

Updated Category News Views 22

Revolutionizing Automotive Sales Analytics Look at Clarivoy, shaking up the auto sales world with a beefed-up platform tailored for the folks who've been craving some straight-shooting insights. We're talking no more guessing games with your marketing dollars. As of November 2, 2026, Clarivoy's latest iteration leaps forward, sporting tools built to dissect every nook and...

Continue Reading
WeSalute's 'Heroes Meet Heroes' Unites Military, Athletes

Updated Category News Views 52

Every now and then, something stirs the soul in a way that neither Wall Street nor Main Street quite can. The 14th annual 'Heroes Meet Heroes' event by WeSalute is poised to do just that. Celebrating Service Through Shared Experiences WeSalute has been a cornerstone for veteran recognition for over two decades, fostering a sense of unity between military service members...

Continue Reading
Zuellig Pharma Expands Clinical Capabilities in China

Updated Category News Views 34

Zuellig Pharma's Strategic Leap in Hangzhou You know, in the ever-evolving world of biotech and pharmaceuticals, setting up shop in the right locale can mean the difference between breakthroughs and breakdowns. So Zuellig Pharma—a major player, but not exactly a household ticker—made a smart move acquiring a clinical facility in Hangzhou. This is no minor shuffle;...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 42

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
Doximity Faces Class Action: Investor Guidance Needed

Updated Category News Views 54

Doximity Lands in Hot Water: The Stakes for Investors Alright, traders, there's a storm brewing around Doximity (NYSE:DOCS), and it's a doozy. A class action lawsuit has been slapped on this digital platform for medical pros, and the accusations are serious. If you rode the wave and snagged yourself some shares between August 8, 2024, and May 13, 2026, you're right in the...

Continue Reading
Systemair Wins First Natural Refrigerant Heat Pump Deal

Updated Category News Views 0

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...

Continue Reading
Yum China Delivers Strong Q3 2026 Results Again

Updated Category News Views 93

A Steady March Forward for Yum China Yum China's third-quarter results reveal a company moving like a well-oiled machine, even in a turbulent market. A revenue uptick of 8% is no small feat, especially when operating under the weight of a 3% rise in system sales that neatly sidesteps the usual foreign exchange hiccups. This ain't just about keeping the lights on; it's...

Continue Reading
Ian Marx Wins Pro Bono Honor at NJ Legal Awards

Updated Category News Views 58

A Champion in Legal Advocacy How often do we hear about a lawyer choosing the unglamorous path of pro bono work over the high-stakes allure of corporate law? Slam-dunk, you don’t. At the New Jersey Legal Awards, Ian S. Marx from Greenberg Traurig broke the mold, snagging the 'Pro Bono Lawyer of the Year' award. This isn’t just some pat on the back; it's recognition of...

Continue Reading
Stephanie Knepp Joins Exceptional Women Alliance

Updated Category News Views 105

A New Chapter for a Seasoned Leader When a high flyer like Stephanie Knepp steps into a new arena, you know folks are going to sit up and pay attention. This time, she's making waves by joining the Exceptional Women Alliance (EWA), a heavy-hitting community of women leaders. With her extensive background in scaling businesses and empowering leaders, she's bound to bring...

Continue Reading

Top 5 Most Recently Viewed Articles

Assystem Reports Key Liquidity Contract Details for Investors

Updated Category News Views 141

Half-Year Liquidity Contract Statement from Assystem Assystem S.A., a prominent player in the nuclear engineering sector, recently disclosed important information regarding its liquidity contract as of June 30, 2025. The company, which focuses on optimizing performance in highly regulated industries, has numerous commitments aimed at forging a low-carbon future. This...

Continue Reading
Clear Channel Outdoor to Divest Spain Business to Atresmedia

Updated Category News Views 215

Clear Channel Outdoor Sells Spanish Operations to Atresmedia Clear Channel Outdoor Holdings, Inc. (NYSE: CCO) has made a significant decision to divest its operations in Spain by entering into a definitive agreement with Atresmedia Corporación de Medios de Comunicación, S.A. This move indicates the company's intent to focus its resources and attention on its core...

Continue Reading
Air Taxi Stocks Soar Following Vertical Aerospace Funding Update

Updated Category News Views 254

Air Taxi Industry Reacts to Major Investment Recently, the air taxi industry experienced a remarkable surge in stock values, spurred by an exciting investment in Vertical Aerospace. This company focuses on electric vertical take-off and landing (eVTOL) aircraft and made headlines after securing new funding that saw its stock price soar by 40%. Within this context,...

Continue Reading
Citius Oncology and Er-Kim Collaborate for LYMPHIR Expansion

Updated Category News Views 197

Citius Oncology and Er-Kim Collaborate for LYMPHIR Expansion In an exciting partnership, Citius Oncology, Inc. (Nasdaq: CTOR) has entered into an exclusive agreement with Er-Kim ?laç Sanayi ve Ticaret A.?. to distribute LYMPHIR (denileukin diftitox-cxdl) across Turkey and several Middle Eastern countries. This collaboration aims to enhance the availability of this...

Continue Reading
Nio's Recent Surge: Boosting Deliveries and Cash Flow

Updated Category News Views 207

Nio's resounding success back in 2024 sent shockwaves through the electric vehicle (EV) sector, with shares surging an impressive 65% as traders caught wind of the delivery numbers. The sentiment from investors was clear: 'Let the good times roll'. Nio wasn't just riding a short-lived wave; they had solid fundamentals undergirding their gains. A combination of new model...

Continue Reading